Compare Torrent Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA PIRAMAL ENTERPRISES TORRENT PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 54.8 17.2 319.3% View Chart
P/BV x 6.6 1.1 576.0% View Chart
Dividend Yield % 0.8 1.6 50.2%  

Financials

 TORRENT PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
PIRAMAL ENTERPRISES
Mar-19
TORRENT PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,5503,303 46.9%   
Low Rs1,1441,797 63.6%   
Sales per share (Unadj.) Rs354.7716.5 49.5%  
Earnings per share (Unadj.) Rs40.179.7 50.3%  
Cash flow per share (Unadj.) Rs64.2107.9 59.5%  
Dividends per share (Unadj.) Rs14.0028.00 50.0%  
Dividend yield (eoy) %1.01.1 94.7%  
Book value per share (Unadj.) Rs273.11,477.5 18.5%  
Shares outstanding (eoy) m169.22184.45 91.7%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.83.6 106.7%   
Avg P/E ratio x33.632.0 105.1%  
P/CF ratio (eoy) x21.023.6 88.7%  
Price / Book Value ratio x4.91.7 285.7%  
Dividend payout %34.935.1 99.4%   
Avg Mkt Cap Rs m227,897470,292 48.5%   
No. of employees `00014.77.8 188.0%   
Total wages/salary Rs m11,35322,504 50.4%   
Avg. sales/employee Rs Th4,083.016,899.4 24.2%   
Avg. wages/employee Rs Th772.32,877.7 26.8%   
Avg. net profit/employee Rs Th461.31,879.9 24.5%   
INCOME DATA
Net Sales Rs m60,021132,153 45.4%  
Other income Rs m2,9883,128 95.5%   
Total revenues Rs m63,009135,281 46.6%   
Gross profit Rs m13,49366,290 20.4%  
Depreciation Rs m4,0865,202 78.6%   
Interest Rs m3,08544,097 7.0%   
Profit before tax Rs m9,31020,119 46.3%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5298,611 29.4%   
Profit after tax Rs m6,78114,701 46.1%  
Gross profit margin %22.550.2 44.8%  
Effective tax rate %27.242.8 63.5%   
Net profit margin %11.311.1 101.6%  
BALANCE SHEET DATA
Current assets Rs m52,623122,742 42.9%   
Current liabilities Rs m52,022310,810 16.7%   
Net working cap to sales %1.0-142.3 -0.7%  
Current ratio x1.00.4 256.1%  
Inventory Days Days12023 518.4%  
Debtors Days Days7639 196.3%  
Net fixed assets Rs m85,016116,904 72.7%   
Share capital Rs m846369 229.4%   
"Free" reserves Rs m45,376272,161 16.7%   
Net worth Rs m46,222272,530 17.0%   
Long term debt Rs m41,115270,196 15.2%   
Total assets Rs m142,432856,261 16.6%  
Interest coverage x4.01.5 275.9%   
Debt to equity ratio x0.91.0 89.7%  
Sales to assets ratio x0.40.2 273.0%   
Return on assets %6.96.9 100.9%  
Return on equity %14.75.4 272.0%  
Return on capital %14.212.4 114.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58015,200 95.9%   
Fx outflow Rs m3,6004,889 73.6%   
Net fx Rs m10,98010,312 106.5%   
CASH FLOW
From Operations Rs m8,942-115,975 -7.7%  
From Investments Rs m-47,070-8,265 569.5%  
From Financial Activity Rs m34,174107,525 31.8%  
Net Cashflow Rs m-3,655-16,650 22.0%  

Share Holding

Indian Promoters % 71.5 52.9 135.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 4.0 175.5%  
FIIs % 12.6 26.6 47.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 16.5 53.3%  
Shareholders   26,511 93,274 28.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   CIPLA  PFIZER  ALEMBIC PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Marginally Higher; Healthcare Stocks Witness Buying(09:30 am)

Asian share markets are trading on a negative note today as Japanese and Hong Kong shares show losses. The Nikkei 225 is down 0.79% while the Hang Seng is down 1.73%.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Nov 13, 2019 10:29 AM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - GLENMARK PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS